Data gathered: November 18
Alternative Data for Vaxart
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Google Trends | 30 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 62 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 75,728 | Sign up | Sign up | Sign up |
| Twitter Mentions | 26 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California.
| Price | $0.58 |
| Target Price | Sign up |
| Volume | 5,240,000 |
| Market Cap | $132M |
| Year Range | $0.53 - $1.3 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Vaxart, Inc. Reports Third Quarter 2024 Financial Results –November 17 - ETF Daily News |
 |
Vaxart Third Quarter 2024 Earnings: Beats ExpectationsNovember 15 - Yahoo |
Vaxart : Investor Presentation - November 2024November 14 - Finnhub |
|
 |
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...November 13 - Yahoo |
 |
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue EstimatesNovember 13 - Yahoo |
 |
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 4.9M | 4.4M | 490,000 | -14M | -12M | -0.060 |
| Q2 '24 | 6.4M | 5.4M | 1M | -16M | -14M | -0.090 |
| Q1 '24 | 2.2M | 9.4M | -7.2M | -24M | -22M | -0.140 |
| Q4 '23 | 3.2M | 8.3M | -5.1M | -17M | -15M | -0.120 |
| Q3 '23 | 2.1M | 5.1M | -3M | -17M | -16M | -0.110 |
Insider Transactions View All
| Watson W. Mark filed to buy 78,125 shares at $0.7. June 20 '24 |
| Watson W. Mark filed to buy 20,000 shares at $0.8. December 28 '22 |
Similar companies
Read more about Vaxart (VXRT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Vaxart?
The Market Cap of Vaxart is $132M.
What is the current stock price of Vaxart?
Currently, the price of one share of Vaxart stock is $0.58.
How can I analyze the VXRT stock price chart for investment decisions?
The VXRT stock price chart above provides a comprehensive visual representation of Vaxart's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vaxart shares. Our platform offers an up-to-date VXRT stock price chart, along with technical data analysis and alternative data insights.
Does VXRT offer dividends to its shareholders?
As of our latest update, Vaxart (VXRT) does not offer dividends to its shareholders. Investors interested in Vaxart should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Vaxart?
Some of the similar stocks of Vaxart are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.